Entasis Therapeutics Holdings Inc. (ETTX)
$2.19
Rating:
Recommendation:
-
| Symbol | ETTX |
|---|---|
| Price | $2.19 |
| Beta | 1.326 |
| Volume Avg. | - |
| Market Cap | - |
| Shares () | - |
| 52 Week Range | |
| 1y Target Est | - |
| DCF Unlevered | ETTX DCF -> | |
|---|---|---|
| DCF Levered | ETTX LDCF -> | |
| ROE | -112.91% | Strong Sell |
| ROA | -115.20% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | - | |
| P/E | -1.95 | Sell |
| P/B | 3.32 | Strong Buy |
Latest ETTX news
About
Download (Excel)Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.